# US 2012/0253191 A1 · Porphyrin nanovesicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253191 A1
- Document ID: US20120253191A1
- Status: Published application
- Kind: A1
- Application number: 13/502,157
- Filed: 2010-10-05
- Published: 2012-10-04
- Earliest claimed: 2009-10-16
- Assignees: University Health Network
- Inventors: Gang Zheng; Jonathan F. Lovell
- Web page: https://patentgrep.com/patent/US20120253191A1

## CPC

- A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- A61K 47/544: {Phospholipids}
- A61K 49/0036: {Porphyrins (used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546)}
- A61K 49/0084: {liposome, i.e. bilayered vesicular structure}
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y10T 428/2991: Coated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The application relates to a nanovesicle comprising a bilayer of at least 15 mol % porphyrin-phospholipid conjugate, wherein the conjugate comprises a porphyrin, porphyrin derivative or porphyrin analog covalently attached to the phospholipid side chain. The nanovesicle can be used for photothermal therapy, photoacoustic imaging, and fluorescence imaging. The application also discloses a method of preparing the said nanovesicle.

## Claims

### Claim 1

A nanovesicle comprising a bilayer of at least 15 molar % porphyrin-phospholipid conjugate, wherein the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid.

### Claim 2 (depends on 1)

The nanovesicle of claim 1 comprising at least 25, 35, 45, 55, 65, 75, 85 or 95 molar % porphyrin-phospholipid conjugate.

### Claim at position 3

3-10. (canceled)

### Claim 10 (depends on 1)

The nanovesicle of claim 1 wherein the porphyrin, porphyrin derivative or porphyrin analog in the porphyrin-phospholipid conjugate is selected from the group consisting of hematoporphyrin, protoporphyrin, tetraphenylporphyrin, a pyropheophorbide, a bacteriochlorophyll, chlorophyll a, a benzoporphyrin derivative, a tetrahydroxyphenyl chlorin, a purpurin, a benzochlorin, a naphthochlorins, a verdin, a rhodin, a keto chlorin, an azachlorin, a bacteriochlorin, a tolyporphyrin, a benzobacteriochlorin, an expanded porphyrin and a porphyrin isomer.

### Claim 11 (depends on 10)

The nanovesicle of claim 10, wherein the expanded porphyrin is a texaphyrin, a sapphyrin or a hexaphyrin and the porphyrin isomer is a porphycene, an inverted porphyrin, a phthalocyanine, or a naphthalocyanine.

### Claim 12 (depends on 1)

The nanovesicle of claim 1 wherein the phospholipid in the porphyrin-phospholipid conjugate comprises phosphatidylcholine, phosphatidylethanoloamine, phosphatidylserine or phosphatidylinositol.

### Claim 13 (depends on 12)

The nanovesicle of claim 12, wherein the phospholipid comprises an acyl side chain of 12 to 22 carbons.

### Claim 14 (depends on 1)

The nanovesicle of claim 1 wherein the porphyrin in the porphyrin-phospholipid conjugate is pyropheophorbide-a acid.

### Claim 15 (depends on 1)

The nanovesicle of claim 1 wherein the porphyrin in the porphyrin-phospholipid conjugate is a bacteriochlorophyll derivate.

### Claim 16 (depends on 1)

The nanovesicle of claim 1 wherein the phospholipid in the porphyrin-phospholipid conjugate is 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphocholine.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The nanovesicle of claim 1 wherein the porphyrin-phospholipid conjugate is oxy-bacteriochlorophyll-lipid.

### Claim 19 (depends on 1)

The nanovesicle of claim 1 wherein the porphyrin is conjugated to the glycerol group on the phospholipid by a carbon chain linker of 0 to 20 carbons.

### Claim 20 (depends on 1)

The nanovesicle of claim 1 further comprising Polyelthylene glycol (PEG).

### Claim 21 (depends on 1)

The nanovesicle of claim 1 further comprising PEG-lipid.

### Claim 22 (depends on 1)

The nanovesicle of claim 1 further comprising PEG-DSPE.

### Claim 23 (depends on 20)

The nanovesicle of claim 20 wherein the PEG is present in an amount of about 5 molar %.

### Claim 24 (depends on 1)

The nanovesicle of claim 1, wherein the nanovesicle is substantially spherical and between about 30 nm at about 200 nm in diameter.

### Claim 25 (depends on 1)

The nanovesicle of claim 1, wherein the nanovesicle is substantially spherical and about 100 nm in diameter.

### Claim 26 (depends on 1)

The nanovesicle of claim 1, wherein the nanovesicle is substantially spherical and about 30 nm in diameter.

### Claim 27 (depends on 1)

The nanovesicle of claim 1, wherein the porphyrin-phospholipid conjugate comprises a metal chelated therein, optionally a radioisotope of a metal.

### Claim 28 (depends on 27)

The nanovesicle of claim 27 wherein the metal is selected from the group consisting of Zn, Cu and Pd.

### Claim 29 (depends on 1)

The nanovesicle of claim 1, further comprising an active agent encapsulated therein, preferably a therapeutic agent or a diagnostic agent, preferably a chemotherapy agent such as doxorubicin.

### Claim 30 (depends on 1)

The nanovesicle of claim 1, further comprising a targeting molecule, preferably an antibody, peptide or aptamer.

### Claim 31 (depends on 30)

The nanovesicle of claim 30, wherein the targeting molecule is folic acid.

### Claim 32 (depends on 1)

The nanovesicle of claim 1, wherein the bilayer further comprises cholesterol, preferably between 30-50 molar % cholesterol.

### Claim 33

A method of preparing a nanovesicle, comprising:
a. mixing a porphyrin-phospholipid conjugate in buffer, wherein the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 and/or the sn-2 position, of one phospholipid;
b. extruding or sonicating the mixture of step (a) to yield a porphyrin-phospholipid bilayer nanovesicle comprising a bilayer of at least 15 molar % porphyrin-phospholipid conjugate.

### Claim 34 (depends on 33)

The method of claim 33, wherein the porphyrin-phospholipid conjugate comprises a metal chelated therein.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

A method of performing photodynamic therapy on a target area in a subject comprising:
a. providing the nanovesicle of claim 1;
b. administering the nanovesicle to the subject; and
c. irradiating the nanovesicle at the target area with a wavelength of light, wherein the wavelength of light activates the porphyrin-phospholipid conjugate to generate singlet oxygen.

### Claim 37 (depends on 36)

The method of claim 36, wherein the nanovesicle is irradiated in a quenched state.

### Claim 38 (depends on 1)

A method of performing photothermal therapy on a target in a subject comprising:
a. providing the nanovesicle of claim 1;
b. administering the nanovesicle to the subject; and
c. irradiating the nanovesicle at the target area with a wavelength of light, wherein the wavelength of light increases the temperature of nanovesicle.

### Claim 39 (depends on 38)

The method of claim 38, wherein the nanovesicle is irradiated in an unquenched state.

### Claim 40 (depends on 1)

A method of imaging a target area in a subject, comprising
a. providing the nanovesicle of claim 1;
b. administering the nanovesicle to the subject;
c. optionally irradiating the nanovesicle at the target area with a wavelength of light, wherein the nanovesicle emits a photoacoustic signal in response to the wavelength of light; and
d. measuring and/or detecting fluorescence or the photoacoustic signal at the target area.

### Claim at position 35

41-46. (canceled)
